Global Health Limited Announces June 2025 Quarterly Business Activity Report

28 Jul Global Health Limited Announces June 2025 Quarterly Business Activity Report

Global Health Limited (ASX: GLH) (“Global Health” or “the Group”) is pleased to release its Appendix 4C Cash Flow Report for the quarter ended 30 June 2025, and the accompanying Quarterly Business Activity Report. The financial performance commentary for the June-2025 quarter is relative to the Previous Corresponding Period (PCP) being the June-2024 quarter.

Financial estimates of revenue, expenses and profitability are subject to audit.

Financial Commentary

The June quarter featured over $700K of new sales orders with new sales for the financial year up 65% on the 12 months to June-24, to over $2.4M.

The order values above represent Implementation Services and first year Annual Recurring Revenue (ARR) only. Most of the June quarter sales orders will be delivered in the subsequent quarters over FY2026.

The bulk of the sales were in support of Mental Health Service Providers and featured the Company’s MasterCare Plus platform integrated with the Company’s HotHealth Digital Front Door. Annual Recurring Revenue (ARR) from the Company’s SaaS platforms now represent 30% of total ARR.

Research and Development expenditure in the June quarter was 20% less than the previous (March-25) quarter with the full year investment in R&D reduced by $600K; from $2.7M in FY24 to $2.1M in FY25. This represents a 30% reduction Year-on-Year. A federal government R&D rebate of approximately $700K is forecast to be received in the next few months.

The remaining features to fully replace our legacy PAS, EMR and PrimaryClinic applications with our MasterCare Plus composable SaaS platform is largely the Patient Administration functionality for hospitals. This is targeted for completion by June 2026.

The Company’s Lifecard Personal Health Record for consumer empowerment and active engagement of consumers with their care team is due for completion in the next few months.

As the major R&D approaches completion, the associated investment will reduce to approximately 18% of total expenses with a focus on incorporating Artificial Intelligence across our portfolio.

AI: Doing more with Less

The Company established an AI executive group in 2024 to research and implement AI within the Company’s operations. This is well underway across all departments and is delivering measurable gains in productivity across the group. This is expected to deliver further reduction of expenses into the future.

With the on-going financial pressure on the healthcare industry, growing demand and a workforce under stress, healthcare service providers will need AI within their workflow to “do-more-with-less”.

Progressively incorporating AI into our customer product portfolio is underway with regular market releases planned in the current financial year.

Financial Highlights

Closing Cash of $1,383K is $551K above Mar-25 Qtr.

The closing cash of $1,383K at the end of the June quarter was a 66% increase on the previous, March-25 closing cash position.

Operating and investing cashflow was largely in line with the PCP (June-24 Qtr).

There is a strong backlog of orders due for fulfilment in FY26. With the continued control of costs and adoption of AI, the Company is targeting a return to profitable and cashflow positive operations over the 12 months to June 2026.

Forward outlook & growth strategy

The Australian Healthcare Sector remains challenged.

• The Public Healthcare Sector, funded by State Governments, have been subject increased funding constraints due to the deficits of State Governments. This is expected to continue for the foreseeable future.
• Public Healthcare services are experiencing increased demand for its services. Increased operating costs, especially labour and energy costs continue to put pressure on their funding.
• Private hospitals are facing funding from private health insurers failing to keep up with increased costs of labour, energy, and funding interest costs.
• Private hospitals are beginning to see increases in occupancy to pre-covid levels, however it remains to be seen whether the increased occupancy trend continues.

With these operating pressures, Healthcare providers are looking to digitise the data across their operations. This is recognised a key pre-requisite for the adoption of AI to “do-more-with-less”.

This combination of data digitisation and the adoption of AI is accepted as the logical solution to the current challenges.

With our patient-centric portfolio of SaaS platforms that encompass the patient journey, Global Health are well positioned as a catalyst to positive change for the healthcare sector.

As the R&D investment tapers to normal levels for technology, funds will be re-directed from R&D to market growth. With remote services now the norm, the Company is well placed to develop new revenues from both the domestic and international markets.

Required disclosures in accordance with Listing Rule 4.7C

In accordance with Listing Rule 4.7C.1, the operating expenditures of Global Health for the quarter ended 30 June 2025 are set out in the table below:

In accordance with Listing Rule 4.7C.3, payments to related parties and their associates during the quarter totalled $82K. This related to directors’ remuneration.

This ASX announcement has been authorised by the Board of Global Health Limited (ASX:GLH).

For the full announcement including the Appendix 4C, please visit the ASX website here.